Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaWEINBERG, J. Brice; VOLKHEIMER, Alicia D; RIZZIERI, David A et al.American journal of hematology. 2007, Vol 82, Num 12, pp 1063-1070, issn 0361-8609, 8 p.Article

Randomized controlled trial of azacitidine in Patients with the myelodysplastic syndrome: A study of the cancer and leukemia group BSILVERMAN, Lewis R; DEMAKOS, Erin P; ELLERTON, John et al.Journal of clinical oncology. 2002, Vol 20, Num 10, pp 2429-2440, issn 0732-183XArticle

Outcomes of Patients Who Undergo Aggressive Induction Therapy for Secondary Acute Myeloid LeukemiaRIZZIERI, David A; O'BRIEN, Jenny A; MOORE, Joseph O et al.Cancer. 2009, Vol 115, Num 13, pp 2922-2929, issn 0008-543X, 8 p.Article

Phase I evaluation of Prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaRIZZIERI, David A; IBOM, Valerie K; GASPARETTO, Christina et al.Clinical cancer research. 2003, Vol 9, Num 2, pp 663-668, issn 1078-0432, 6 p.Article

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaBASS, Adam J; GOCKERMAN, Jon P; RIZZIERI, David A et al.Journal of clinical oncology. 2002, Vol 20, Num 13, pp 2995-3000, issn 0732-183XArticle

Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemiaRIZZIERI, David A; BASS, Adam J; JACOBSON, Robert et al.Journal of clinical oncology. 2002, Vol 20, Num 3, pp 674-679, issn 0732-183XArticle